Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Insulin Lispro · Admelog, Humalog

Recombinant protein · Agonist of insulin receptor (INSR) · developed by Lilly

Approved FDA, Jun 1996

What is Insulin Lispro?

Insulin lispro is a rapid-acting human insulin analog that binds the insulin receptor to regulate glucose metabolism. It stimulates peripheral glucose uptake by skeletal muscle and fat, inhibits hepatic glucose production, and enhances protein synthesis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Admelog, Humalog, Humalog Mix50/50 Kwikpen, Lyumjev, LY-900014, LY-275585, Lispro SC
Drug type: Recombinant protein
Targets: insulin receptor (INSR)
Mechanism: Agonist of insulin receptor (INSR)
Pathways: glucose uptake, glucose metabolism, protein synthesis
Therapy area: Endocrine
Developer: Lilly
In trials of: LLY
FDA status: Approved as Admelog, Humalog, Humalog Mix50/50 Kwikpen (June 14, 1996), BLA020563 · FDA label
UNII: GFX7QIS1II

✅ FDA-approved uses

Diabetes mellitus (Lyumjev)
Diabetes mellitus (Humalog)
Diabetes mellitus (Admelog)

From the indications section of the FDA label (version of Jun 16, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Other drugs acting on INSR

Insulin Degludec FDA approved Insulin Glargine FDA approved Injectable insulin Phase 3 Injected insulin Phase 3 ORMD-0801 Phase 3

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z